Nagaraja N V, Singh S K, Gupta R C
Pharmacokinetics and Metabolism Division, Central Drug Research Institute, Lucknow, India.
J Chromatogr B Biomed Appl. 1995 Feb 17;664(2):472-7. doi: 10.1016/0378-4347(94)00475-k.
A sensitive high-performance liquid chromatographic assay has been developed and validated for the determination of methyl N-[5-[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]-1H-benzimidazol-2-y l d carbamate (CDRI compound 81/470) in normal rat blood. The method described herein is simple, with improved selectivity and sensitivity over a previously reported HPLC method. The limit of quantitation is 10 ng/ml (method 1) and 2.5 ng/ml (method 2) in blood, as compared with 40 ng/ml for the previous method. The standard curve in blood is linear over the concentration range 10-1000 ng/ml in method 1 and 2.5-1000 ng/ml in method 2 and the extraction recovery is higher than 80% for both methods.
已开发并验证了一种灵敏的高效液相色谱法，用于测定正常大鼠血液中N-[5-[[4-(2-吡啶基)-1-哌嗪基]羰基]-1H-苯并咪唑-2-基]氨基甲酸甲酯（CDRI化合物81/470）。本文所述方法简单，与先前报道的HPLC方法相比，选择性和灵敏度有所提高。血液中的定量限在方法1中为10 ng/ml，在方法2中为2.5 ng/ml，而先前方法为40 ng/ml。方法1中血液的标准曲线在10-1000 ng/ml浓度范围内呈线性，方法2中在2.5-1000 ng/ml浓度范围内呈线性，两种方法的提取回收率均高于80%。
